Nippon Shinyaku Co., Ltd. and Janssen Pharmaceutical K.K. to Jointly Develop New Oral Immediately-Release Painkiller
Tramadol hydrochloride, a compound discovered by Germany-based Grunenthal, came to the German market in 1981 as an oral immediate-release formulation. Since then, various formulations containing tramadol hydrochloride have been launched in more than 100 countries worldwide.
Nippon Shinyaku concluded a license agreement for tramadol hydrochloride immediate-release formulation in 1996 and has proceeded with its clinical development for cancer pain since then. Under this tripartite agreement, Janssen Pharmaceutical will develop this formulation for treating non-malignant pain. Nippon Shinyaku and Janssen Pharmaceutical plan to develop its indication separately, but submit for its NDA application simultaneously and distribute it under different trademarks.
Most read news
Organizations
Other news from the department business & finance
Get the chemical industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.